AKTS compared with EIKN: revenue, margins and what each company keeps, and the suppliers and customers both name

AKTSAktis Oncology, Inc.

Mkt capRevenueRevenue

EIKNEikon Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

AKTSAktis Oncology, Inc.

EIKNEikon Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only AKTS 0

None

Shared 0

No disclosed counterparties: AKTS.

Only EIKN 4

MRKMSD International Business GmbHsupplier

—Impact Therapeutics (Shanghai)unlistedsupplier

—Seven and Eight Biotherapeuticsunlistedsupplier

—Superb Wisdomunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

AKTSAktis Oncology, Inc.

15.87▲+6.88%· post 15.87

Mkt cap$874.8MRevenue$3MQ2 FY26

EIKNEikon Therapeutics, Inc.

5.96▲+2.01%· post 5.96

ClosedNov 6 '26

Mkt cap$319.4MRevenue—

Compare

ClosedNov 6 '26

AKTSAktis Oncology, Inc.

EIKNEikon Therapeutics, Inc.

15.87▲+6.88%post 15.87

Price

5.96▲+2.01%post 5.96

$874.8M

Mkt cap

$319.4M

Q2 FY26$3M

Revenue

—

AKTS15.87▲+6.88%vsEIKN5.96▲+2.01%ClosedNov 6 '26